Published in Gene Therapy Weekly, November 10th, 1997
RCC is an immunogenic malignancy. Its antitumor immune responses are mediated primarily by major histocompatibility cell (MHC) class I antigens which stimulate T cells. However, for the initiation of CD4+ T cells, MHC class II antigens are required. These T cells induce proliferation of CD8 positive cytotoxic T lymphocytes (CTL), which act as effectors on tumor target cells. RCC generally presents MHC class I antigens but lacks MHC class II antigens. Both MHC antigens must be present on the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.